New molecular targets and proof-of-concept therapies for Autism Spectrum Disorders

Project description

Shrinking the autism research gap

Diagnosed before age 3 based on behavioural cues, autism is a major multifactorial neurodevelopmental disorder, affecting 1 in 100 child births worldwide. There is no cure and what is more, there is no one size fits all approach to autism management. The EU-funded THERAUTISM project will aim to shrink the autism research gap to expose the common molecular and cellular dysfunctions underlying autism-related behaviours. It will also investigate the possibility for a safe gene therapy vector – after it takes into account the properties of a new protein function to restore this new target and rescue social deficits in different preclinical models of autism. The aim is to validate new molecular therapeutic targets.

Fields of science

• natural sciences › biological sciences › neurobiology
• medical and health sciences › medical biotechnology › genetic engineering › gene therapy
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs
• natural sciences › biological sciences › biochemistry › biomolecules › proteins

Programme(s)

• H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme

Topic(s)

• ERC-2019-STG - ERC Starting Grant

Call for proposal

ERC-2019-STG

See other projects for this call

Funding Scheme

ERC-STG - Starting Grant

Host institution

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

Net EU contribution

€ 1 499 025,00

Address

Rue Michel Ange 3
75794 Paris
France

Region

Ile-de-France › Ile-de-France › Paris

Activity type

Research Organisations

Links

Non-EU contribution

€ 0,00

Beneficiaries (1)

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

Net EU contribution

€ 1 499 025,00

Address

Rue Michel Ange 3
75794 Paris

Region

Ile-de-France › Ile-de-France › Paris

Activity type

Research Organisations

Links

Non-EU contribution

€ 0,00